# EDGAR Filing Document

**Accession Number:** 0001401914
**File Stem:** 0001493152-26-013353
**Filing Date:** 2026-3
**Character Count:** 28484
**Document Hash:** 92c08e9a6785e79da5d6e0c1525f06e2
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-013353.hdr.sgml**: 20260330

**ACCESSION NUMBER**: 0001493152-26-013353

**CONFORMED SUBMISSION TYPE**: 1-A POS

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20260330

**DATE AS OF CHANGE**: 20260327

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Dare Bioscience, Inc.
- **CENTRAL INDEX KEY:** 0001401914
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 204139823
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 1-A POS
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 024-12688
- **FILM NUMBER:** 26809491

**BUSINESS ADDRESS:**
- **STREET 1:** 3655 NOBEL DRIVE
- **STREET 2:** SUITE 260
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122
- **BUSINESS PHONE:** 858-926-7655

**MAIL ADDRESS:**
- **STREET 1:** 3655 NOBEL DRIVE
- **STREET 2:** SUITE 260
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92122

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Cerulean Pharma Inc.
- **DATE OF NAME CHANGE:** 20090714

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Tempo Pharmaceuticals Inc
- **DATE OF NAME CHANGE:** 20070604

## Part

**Post-Qualification Amendment No. 1**

**File No. 024-12688**

**EXPLANATORY NOTE**

This Post-Qualification Amendment No. 1 to the Offering Statement on Form 1-A (File No. 024-12688) (the "Offering Statement") filed by Daré Bioscience, Inc. is being filed to include as an exhibit the consent of Haskell & White LLP to the use of its report dated March 26, 2026 with respect to the financial statements of Daré Bioscience, Inc. included in the Offering Statement, and to otherwise update the exhibits in the exhibit index.

**EXHIBIT INDEX**

Exhibits not filed or furnished herewith are incorporated by reference to exhibits previously filed with the SEC, as reflected in the table below.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | |
| <br>**Exhibit<br> Number** | <br>**Description of Exhibit** | **Form** | **File No.** | **Filing Date** | **Exhibit No.** | <br>**Filed Herewith** |
| *UNDERWRITING AGREEMENT* | *UNDERWRITING AGREEMENT* | *UNDERWRITING AGREEMENT* | *UNDERWRITING AGREEMENT* | *UNDERWRITING AGREEMENT* | *UNDERWRITING AGREEMENT* | *UNDERWRITING AGREEMENT* |
| 1.1 | [Selling Agency Agreement, dated January 5, 2026, between Daré Bioscience, Inc. and Digital Offering, LLC](https://www.sec.gov/Archives/edgar/data/1401914/000149315226004245/ex1-1.htm) | 8-K | 001-36395 | 01/29/2026 | 1.1 |  |
| *CHARTER AND BYLAWS* | *CHARTER AND BYLAWS* | *CHARTER AND BYLAWS* | *CHARTER AND BYLAWS* | *CHARTER AND BYLAWS* | *CHARTER AND BYLAWS* | *CHARTER AND BYLAWS* |
| 2.1 | [Restated Certificate of Incorporation, as amended to date](https://www.sec.gov/Archives/edgar/data/1401914/000140191424000038/exhibit31_amendedandrestat.htm) | 10-Q | 001-36395 | 08/12/2024 | 3.1 |  |
| 2.2 | [Third Amended and Restated By-Laws (as amended through January 24, 2023](https://www.sec.gov/Archives/edgar/data/1401914/000140191424000033/dare-arbylawsjan20234856.htm)) | 10-Q | 001-36395 | 5/14/2024 | 3.1 |  |
| 2.3 | [Certificate of Designation of Series A Convertible Preferred Stock](https://www.sec.gov/Archives/edgar/data/1401914/000149315226004245/ex3-1.htm) | 8-K | 001-36395 | 01/29/2026 | 3.1 |  |
| *INSTRUMENTS DEFINING RIGHTS OF SECURITY HOLDERS* | *INSTRUMENTS DEFINING RIGHTS OF SECURITY HOLDERS* | *INSTRUMENTS DEFINING RIGHTS OF SECURITY HOLDERS* | *INSTRUMENTS DEFINING RIGHTS OF SECURITY HOLDERS* | *INSTRUMENTS DEFINING RIGHTS OF SECURITY HOLDERS* | *INSTRUMENTS DEFINING RIGHTS OF SECURITY HOLDERS* | *INSTRUMENTS DEFINING RIGHTS OF SECURITY HOLDERS* |
| 3.1 | [Specimen stock certificate evidencing the shares of common stock](https://www.sec.gov/Archives/edgar/data/1401914/000156459018006989/dare-ex41_433.htm) | 10-K | 001-36395 | 03/28/2018 | 4.1 |  |
| 3.2 | [Warrant Agreement to purchase shares of common stock of the registrant with Aquilo Partners, L.P., entered into as of October 16, 2016.](https://www.sec.gov/Archives/edgar/data/1401914/000140191422000032/ex42_10kx2021.htm) | 10-K | 001-36395 | 03/31/2022 | 4.2 |  |
| 3.3 | [Form of common stock purchase warrants issued on September 1, 2023](https://www.sec.gov/Archives/edgar/data/1401914/000149315223030659/ex4-1.htm) | 8-K | 001-36395 | 08/30/2023 | 4.1 |  |
| 3.4 | [Form of common stock purchase warrants issued on December 21, 2023](https://www.sec.gov/Archives/edgar/data/1401914/000140191424000016/dare-20231231xex44.htm) | 10-K | 001-36395 | 03/28/2024 | 4.4 |  |
| 3.5 | [Description of securities of the registrant](https://www.sec.gov/Archives/edgar/data/1401914/000140191420000042/exhibit46.htm) | 10-K | 001-36395 | 03/27/2020 | 4.6 |  |
| 3.6 | [Form of Investor Warrant](https://www.sec.gov/Archives/edgar/data/1401914/000149315226004245/ex4-1.htm) | 8-K | 001-36395 | 01/29/2026 | 4.1 |  |
| 3.7 | [Form of Agent Unit Warrant](https://www.sec.gov/Archives/edgar/data/1401914/000149315226004245/ex4-2.htm) | 8-K | 001-36395 | 01/29/2026 | 4.2 |  |
| 3.8 | [Form of Agent Common Warrant (included in Exhibit 3.7)](https://www.sec.gov/Archives/edgar/data/1401914/000149315226004245/ex4-2.htm) | 8-K | 001-36395 | 01/29/2026 | 4.3 |  |
| *SUBSCRIPTION AGREEMENT* | *SUBSCRIPTION AGREEMENT* | *SUBSCRIPTION AGREEMENT* | *SUBSCRIPTION AGREEMENT* | *SUBSCRIPTION AGREEMENT* | *SUBSCRIPTION AGREEMENT* | *SUBSCRIPTION AGREEMENT* |
| 4.1 | [Form of Subscription Agreement](https://www.sec.gov/Archives/edgar/data/1401914/000149315226004245/ex10-1.htm) | 8-K | 001-36395 | 01/29/2026 | 10.1 |  |
| *MATERIAL CONTRACTS* | *MATERIAL CONTRACTS* | *MATERIAL CONTRACTS* | *MATERIAL CONTRACTS* | *MATERIAL CONTRACTS* | *MATERIAL CONTRACTS* | *MATERIAL CONTRACTS* |
| 6.1(a)+ | [Exclusive License Agreement dated March 31, 2022 between Organon International GmbH and Dare Bioscience, Inc., effective as of June 30, 2022](https://www.sec.gov/Archives/edgar/data/1401914/000140191422000051/ex101_10q033122.htm) | 10-Q | 001-36395 | 05/12/2022 | 10.1 |  |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| 6.1(b)+ | [First Amendment to License Agreement by and between Organon International GmbH and Dare Bioscience, Inc. entered into as of July 4, 2023](https://www.sec.gov/Archives/edgar/data/1401914/000140191423000048/exhibit102_10q20230930.htm) | 10-Q | 001-36395 | 11/09/2023 | 10.2 |
| 6.2+ | [Consent, Waiver and Stand-By License Agreement, dated March 30, 2022, by and among TriLogic Pharma, LLC, and MilanaPharm LLC, Dare Bioscience, Inc., and Organon International GmbH.](https://www.sec.gov/Archives/edgar/data/1401914/000140191422000051/ex102_10q033122.htm) | 10-Q | 001-36395 | 05/12/2022 | 10.2 |
| 6.3Δ | [License and Collaboration Agreement dated February 11, 2018 between Daré Bioscience, Inc., Strategic Science and Technologies-D, LLC and Strategic Science Technologies, LLC](https://www.sec.gov/Archives/edgar/data/1401914/000119312518143344/d575362dex101.htm) | 10-K/A | 001-36395 | 04/30/2018 | 10.1 |
| 6.4Δ | [License Agreement dated March 19, 2017, between Daré Bioscience Operations, Inc. and ADVA-Tec, Inc.](https://www.sec.gov/Archives/edgar/data/1401914/000156459017023408/dare-ex101_371.htm) | 10-Q | 001-36395 | 11/13/2017 | 10.1 |
| 6.5Δ | [Exclusive License Agreement made as April 24, 2018 by and between Catalent JNP, Inc. (fka Juniper Pharmaceuticals, Inc.), and Daré Bioscience, Inc.](https://www.sec.gov/Archives/edgar/data/1401914/000156459018021487/dare-ex101_230.htm) | 10-Q | 001-36395 | 8/13/2018 | 10.1 |
| 6.6(a)Δ | [Amended and Restated Exclusive License Agreement for Atrophic Vaginitis Technology, effective as of July 14, 2006, dated August 15, 2007, by and between Fred Mermelstein, Ph.D., and Janet Chollet, M.D., and Pear Tree Women's Health Care, Inc.](https://www.sec.gov/Archives/edgar/data/1401914/000156459018021487/dare-ex105_237.htm) | 10-Q | 001-36395 | 8/13/2018 | 10.5 |
| 6.6(b)Δ | [Amendment No. 1 to the Amended and Restated Exclusive License Agreement, dated as of October 10, 2007, by and among Fred Mermelstein, Ph.D. and Janet Chollet, M.D., and Pear Tree Pharmaceuticals, Inc.](https://www.sec.gov/Archives/edgar/data/1401914/000156459018021487/dare-ex106_236.htm) | 10-Q | 001-36395 | 8/13/2018 | 10.6 |
| 6.6(c)Δ | [Amendment No. 2 to the Amended and Restated Exclusive License Agreement, dated as of February 13, 2017, by and among Fred Mermelstein, Ph.D., and Janet Chollet, M.D., Pear Tree Pharmaceuticals, Inc. and Bernadette Klamerus](https://www.sec.gov/Archives/edgar/data/1401914/000156459018021487/dare-ex107_234.htm) | 10-Q | 001-36395 | 8/13/2018 | 10.7 |
| 6.6(d)+ | [Amendment No. 3 to the Amended and Restated Exclusive License Agreement, effective as of February 13, 2017, by and among Fred Mermelstein, Ph.D., and Janet Chollet, M.D., Pear Tree Pharmaceuticals, Inc. and Bernadette Klamerus](https://www.sec.gov/Archives/edgar/data/1401914/000140191423000013/dare-20221231xex106d.htm) | 10-K | 001-36395 | 3/30/2023 | 10.6(d) |
| 6.6(e)Δ | [Exclusive License Agreement, dated as of February 13, 2017, by and between GYN Holdings, Inc., a wholly-owned subsidiary of Pear Tree Pharmaceuticals, Inc. and Bernadette Klamerus](https://www.sec.gov/Archives/edgar/data/1401914/000156459018021487/dare-ex108_235.htm) | 10-Q | 001-36395 | 8/13/2018 | 10.8 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| 6.6(f)Δ | [Exclusive License Agreement, effective as of September 15, 2017, by and between Fred Mermelstein, Ph.D., Janet Chollet, M.D., Pear Tree Pharmaceuticals, Inc., and Stephen C. Rocamboli](https://www.sec.gov/Archives/edgar/data/1401914/000156459018021487/dare-ex109_232.htm) | 10-Q | 001-36395 | 8/13/2018 | 10.9 |
| 6.7(a)Δ | [Assignment Agreement by and between Daré Bioscience, Inc. and Hammock Pharmaceuticals, Inc. effective as of December 5, 2018](https://www.sec.gov/Archives/edgar/data/1401914/000140191419000015/a1010ahammockassignment.htm) | 10-K | 001-36395 | 04/01/2019 | 10.10(a) |
| 6.7(b)Δ | [First Amendment to the License Agreement effective as of December 5, 2018 by and among Daré Bioscience, Inc., TriLogic Pharma, LLC and MilanaPharm LLC](https://www.sec.gov/Archives/edgar/data/1401914/000140191419000015/a1010b1stamtohamcklicnsagr.htm) | 10-K | 001-36395 | 04/01/2019 | 10.10(b) |
| 6.7(c) | [Amendment No. 1 to Assignment Agreement entered into as of December 4, 2019 between Daré Bioscience, Inc. and Hammock Pharmaceuticals, Inc.](https://www.sec.gov/Archives/edgar/data/1401914/000140191420000042/exhibit1010c.htm) | 10-K | 001-36395 | 03/27/2020 | 10.10(c) |
| 6.7(d) | [Amendment No. 2 to the License Agreement entered into as of December 3, 2019 between Daré Bioscience, Inc., TriLogic Pharma, LLC and MilanaPharm LLC](https://www.sec.gov/Archives/edgar/data/1401914/000140191420000042/exhibit1010d.htm) | 10-K | 001-36395 | 03/27/2020 | 10.10(d) |
| 6.7(e) | [Amendment to License Agreement effective as of September 21, 2021 by and among Daré Bioscience, Inc., TriLogic Pharma, LLC and MilanaPharm LLC](https://www.sec.gov/Archives/edgar/data/1401914/000140191421000137/ex101.htm) | 10-Q | 001-36395 | 11/10/2021 | 10.1 |
| 6.8+ | [Cooperative Research and Development Agreement entered into as of July 8, 2021 between Daré Bioscience, Inc. and the Eunice Kennedy Shriver National Institutes of Child Health and Human Development Institute](https://www.sec.gov/Archives/edgar/data/1401914/000140191421000137/ex102.htm) | 10-Q | 001-36395 | 11/10/2021 | 10.2 |
| 6.9+ | [License Agreement dated as of August 12, 2023 between Douglas Pharmaceuticals Limited and Daré Bioscience, Inc.](https://www.sec.gov/Archives/edgar/data/1401914/000140191425000012/ex1010douglaslicenseagre.htm) | 10-K | 001-36395 | 03/31/2025 | 10.10 |
| 6.10+ | [Grant Agreement between Daré Bioscience, Inc. and the Bill & Melinda Gates Foundation effective as of June 30, 2021, as amended to date](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/a1010_foundationgrantagrmt.htm) | 10-K | 001-36395 | 03/26/2026 | 10.10 |
| 6.11+ | [Grant Agreement between Daré Bioscience, Inc. and the Bill & Melinda Gates Foundation effective as of November 11, 2024, as amended to date](https://www.sec.gov/Archives/edgar/data/1401914/000140191425000050/exhibit103_gatesagreemen.htm) | 10-Q | 001-36395 | 11/13/2025 | 10.3 |
| 6.12+ | [Subaward Agreement between the Consortium Management Firm, National Collegiate Inventors and Innovators Alliance, Inc. d/b/a/ VentureWell and Daré Bioscience, Inc., effective as of October 12, 2024](https://www.sec.gov/Archives/edgar/data/1401914/000140191425000012/ex_1013xarpa-h.htm) | 10-K | 001-36395 | 03/31/2025 | 10.13 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| 6.13 | [Royalty Interest Financing Agreement entered into as of December 21, 2023 between Dare Bioscience, Inc. and United in Endeavor, LLC](https://www.sec.gov/Archives/edgar/data/1401914/000140191424000016/dare-20231231xex1012.htm) | 10-K | 001-36395 | 03/28/2024 | 10.12 |
| 6.14 | [Purchase Agreement, dated October 21, 2024, by and between Daré Bioscience, Inc. and Lincoln Park Capital Fund, LLC](https://www.sec.gov/Archives/edgar/data/1401914/000149315224041796/ex10-1.htm) | 8-K | 001-36395 | 10/21/2024 | 10.1 |
| 6.15 | [Registration Rights Agreement, dated October 21, 2024, by and between Daré Bioscience, Inc. and Lincoln Park Capital Fund, LLC](https://www.sec.gov/Archives/edgar/data/1401914/000149315224041796/ex10-2.htm) | 8-K | 001-36395 | 10/21/2024 | 10.2 |
| 6.16+ | [Traditional Royalty Purchase Agreement between Daré Bioscience, Inc. and XOMA (US) LLC, dated as of April 29, 2024](https://www.sec.gov/Archives/edgar/data/1401914/000140191424000038/exhibit101xoma-daretradi.htm) | 10-Q | 001-36395 | 08/12/2024 | 10.1 |
| 6.17+ | [Synthetic Royalty Purchase Agreement between Daré Bioscience, Inc. and XOMA (US) LLC, dated as of April 29, 2024](https://www.sec.gov/Archives/edgar/data/1401914/000140191424000038/xoma-daresyntheticroyalt.htm) | 10-Q | 001-36395 | 08/12/2024 | 10.2 |
| 6.18(a)\* | [Daré Bioscience, Inc. Amended and Restated 2014 Stock Incentive Plan](https://www.sec.gov/Archives/edgar/data/1401914/000119312518216324/d458206dex101.htm) | 8-K | 001-36395 | 7/12/2018 | 10.1 |
| 6.18(b)\* | [Form of Incentive Stock Option Agreement for grants under the Daré Bioscience, Inc. Amended and Restated 2014 Stock Incentive Plan](https://www.sec.gov/Archives/edgar/data/1401914/000156459018021487/dare-ex103_157.htm) | 10-Q | 001-36395 | 8/13/2018 | 10.3 |
| 6.18(c)\* | [Form of Nonstatutory Stock Option Agreement for grants under the Daré Bioscience, Inc. Amended and Restated 2014 Stock Incentive Plan](https://www.sec.gov/Archives/edgar/data/1401914/000156459018021487/dare-ex104_158.htm) | 10-Q | 001-36395 | 8/13/2018 | 10.4 |
| 6.19(a)\* | [Daré Bioscience, Inc. 2022 Stock Incentive Plan](https://www.sec.gov/Archives/edgar/data/1401914/000140191424000038/exhibit107dare-2022stockin.htm) | 10-Q | 001-36395 | 8/12/2024 | 10.7 |
| 6.19(b)\* | [Amendment No. 1 to Daré Bioscience, Inc. 2022 Stock Incentive Plan](https://www.sec.gov/Archives/edgar/data/1401914/000164117225018393/ex10-1.htm) | 8-K | 001-36395 | 7/9/2025 | 10.1 |
| 6.19(c)\* | [Form of Incentive Stock Option Agreement for Grants under the Daré Bioscience, Inc. 2022 Stock Incentive Plan](https://www.sec.gov/Archives/edgar/data/1401914/000149315222017652/ex10-1b.htm) | 8-K | 001-36395 | 6/24/2022 | 10.1(b) |
| 6.19(d)\* | [Form of Nonstatutory Stock Option Agreement for Grants under the Daré Bioscience, Inc. 2022 Stock Incentive Plan](https://www.sec.gov/Archives/edgar/data/1401914/000149315222017652/ex10-1c.htm) | 8-K | 001-36395 | 6/24/2022 | 10.1(c) |
| 6.20\* | [Daré Bioscience, Inc. Performance Bonus Plan, as amended](https://www.sec.gov/Archives/edgar/data/1401914/000140191423000048/ex_103performancebonusplan.htm) | 10-Q | 001-36395 | 11/9/2023 | 10.3 |
| 6.21\* | [Form of indemnification agreement between the registrant and each of its executive officers and directors](https://www.sec.gov/Archives/edgar/data/1401914/000119312514090300/d657877dex1016.htm) | S-1 | 333-194442 | 03/10/2014 | 10.16 |
| 6.22\* | [Amended and Restated Non-Employee Director Compensation Policy (as amended through January 28, 2025)](https://www.sec.gov/Archives/edgar/data/1401914/000140191425000022/ex101_noneedircomp.htm) | 10-Q | 001-36395 | 05/13/2025 | 10.1 |
| 6.23(a)\* | [Employment Agreement by and between Daré Bioscience, Inc. and Sabrina Martucci Johnson dated as of August 15, 2017](https://www.sec.gov/Archives/edgar/data/1401914/000119312517262263/d425695dex101.htm) | 8-K | 001-36395 | 08/18/2017 | 10.1 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| 6.23(b)\* | [Amendment No. 1 to Employment Agreement between Daré Bioscience, Inc. and Sabrina Martucci Johnson dated as of March 9, 2020](https://www.sec.gov/Archives/edgar/data/1401914/000140191420000068/ex1013b.htm) | 10-Q | 001-36395 | 05/14/2020 | 10.13(b) |
| 6.23(c)\* | [Amendment No. 2 to Employment Agreement between Daré Bioscience, Inc. and Sabrina Martucci Johnson, dated as of May 20, 2024](https://www.sec.gov/Archives/edgar/data/1401914/000140191424000038/exhibit105amendmentno2toem.htm) | 10-Q | 001-36395 | 08/12/2024 | 10.5 |
| 6.24\* | [Daré Bioscience, Inc. Change in Control Policy (as amended on April 29, 2024)](https://www.sec.gov/Archives/edgar/data/1401914/000140191424000038/exhibit106darebiosciencein.htm) | 10-Q | 333-251599 | 08/12/2024 | 10.6 |
| *PLAN OF ACQUISITION, REORGANIZATION, ARRANGEMENT, LIQUIDATION, OR SUCCESSION* | *PLAN OF ACQUISITION, REORGANIZATION, ARRANGEMENT, LIQUIDATION, OR SUCCESSION* | *PLAN OF ACQUISITION, REORGANIZATION, ARRANGEMENT, LIQUIDATION, OR SUCCESSION* | *PLAN OF ACQUISITION, REORGANIZATION, ARRANGEMENT, LIQUIDATION, OR SUCCESSION* | *PLAN OF ACQUISITION, REORGANIZATION, ARRANGEMENT, LIQUIDATION, OR SUCCESSION* | *PLAN OF ACQUISITION, REORGANIZATION, ARRANGEMENT, LIQUIDATION, OR SUCCESSION* |
| 7.1§Δ | [Agreement and Plan of Merger, dated as of April 30, 2018, by and among Daré Bioscience, Inc., Daré Merger Sub, Inc., Pear Tree Pharmaceuticals, Inc., and Fred Mermelstein and Stephen C. Rocamboli, as Holders' Representatives](https://www.sec.gov/Archives/edgar/data/1401914/000156459018021487/dare-ex1010_233.htm) | 10-Q | 001-36395 | 8/13/2018 | 10.10 |
| 7.2+ | [Agreement and Plan of Merger, dated November 10, 2019, Dare Bioscience, Inc., MC Merger Sub, Inc., Microchips Biotech, Inc., and Shareholder Representative Services LLC, as the stockholders' representative](https://www.sec.gov/Archives/edgar/data/1401914/000140191419000088/exhibit21.htm) | 8-K | 001-36395 | 11/12/2019 | 2.1 |
| *ESCROW AGREEMENTS* | *ESCROW AGREEMENTS* | *ESCROW AGREEMENTS* | *ESCROW AGREEMENTS* | *ESCROW AGREEMENTS* | *ESCROW AGREEMENTS* |
| 8.1 | [Form of Escrow Agreement among Daré Bioscience, Inc., Digital Offering, LLC, and Wilmington Trust, N.A.](https://www.sec.gov/Archives/edgar/data/1401914/000149315225029450/ex8-1.htm) | 1-A/A | 024-12688 | 12/29/2025 | 8.1 |
| *LETTER RE CHANGE IN CERTIFYING ACCOUNTANT* | *LETTER RE CHANGE IN CERTIFYING ACCOUNTANT* | *LETTER RE CHANGE IN CERTIFYING ACCOUNTANT* | *LETTER RE CHANGE IN CERTIFYING ACCOUNTANT* | *LETTER RE CHANGE IN CERTIFYING ACCOUNTANT* | *LETTER RE CHANGE IN CERTIFYING ACCOUNTANT* |
| 9.1 | [Letter from Mayer Hoffman McCann P.C. dated August 10, 2023](https://www.sec.gov/Archives/edgar/data/1401914/000149315223027449/ex16-1.htm) | 8-K | 001-36395 | 8/10/2023 | 16.1 |
| *POWER OF ATTORNEY* | *POWER OF ATTORNEY* | *POWER OF ATTORNEY* | *POWER OF ATTORNEY* | *POWER OF ATTORNEY* | *POWER OF ATTORNEY* |
| 10.1 | [Power of Attorney (included in the signature page of this Offering Statement)](https://www.sec.gov/Archives/edgar/data/1401914/000149315225024997/partiiandiii.htm#jw_001) | 1-A | 024-12688 | 11/25/2025 | 10.1 |
| *CONSENTS* | *CONSENTS* | *CONSENTS* | *CONSENTS* | *CONSENTS* | *CONSENTS* |
| 11.1 | [Consent of Haskell & White LLP](https://www.sec.gov/Archives/edgar/data/1401914/000140191426000004/dare-20251231xex232.htm) | 10-K | 001-36395 | 03/26/2026 | 23.2 |
| 11.2 | [Consent of Sheppard, Mullin, Richter & Hampton LLP (included in Exhibit 12.1)](https://www.sec.gov/Archives/edgar/data/1401914/000149315225029450/ex12-1.htm) | 1-A/A | 024-12688 | 12/29/2025 | 12.1 |
| *OPINION RE LEGALITY* | *OPINION RE LEGALITY* | *OPINION RE LEGALITY* | *OPINION RE LEGALITY* | *OPINION RE LEGALITY* | *OPINION RE LEGALITY* |
| 12.1 | [Opinion of Sheppard, Mullin, Richter & Hampton LLP](https://www.sec.gov/Archives/edgar/data/1401914/000149315225029450/ex12-1.htm) | 1-A/A | 024-12688 | 12/29/2025 | 12.1 |

---

---

| | |
|:---|:---|
| + | Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(b)(10). The omitted information is not material and would likely cause competitive harm to the Company if publicly disclosed. |
| Δ | Confidential treatment has been requested or granted to certain confidential information contained in this exhibit. |
| \* | Management contract or compensatory plan or arrangement |
| § | All schedules (or similar attachments) have been omitted from this filing pursuant to Item 601(b)(2) of Regulation S-K. The registrant will furnish copies of any schedules to the Securities and Exchange Commission upon request. |

---

**SIGNATURES**

Pursuant to the requirements of Regulation A, the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 1-A and has duly caused this post qualification amendment to the offering statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on March 27, 2026.

---

| | |
|:---|:---|
| **Daré Bioscience, Inc.** | **Daré Bioscience, Inc.** |
| By: | */s/ Sabrina Martucci Johnson* |
|  | Sabrina Martucci Johnson |
|  | Chief Executive Officer and President |

---

This post qualification amendment to the offering statement has been signed by the following persons in the capacities and on the dates indicated:

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Sabrina Martucci Johnson* | Chief Executive Officer, President, Secretary, | March 27, 2026 |
| Sabrina Martucci Johnson | and Director |  |
| */s/ MarDee Haring-Layton* | Chief Accounting Officer | March 27, 2026 |
| MarDee Haring-Layton |  |  |
| *\** | Director | March 27, 2026 |
| Jessica D. Grossman, M.D. |  |  |
| *\** | Director | March 27, 2026 |
| Susan L. Kelley, M.D. |  |  |
| *\** | Director | March 27, 2026 |
| Gregory W. Matz, CPA |  |  |
| *\** | Director | March 27, 2026 |
| William H. Rastetter, Ph.D. |  |  |
| *\** | Director | March 27, 2026 |
| Robin J. Steele, J.D., L.L.M. |  |  |

---

---

| | |
|:---|:---|
| \* By: | */s/ Sabrina Martucci Johnson* |
|  | Sabrina Martucci Johnson |
|  | Attorney-in-fact |

---

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 1-A

### REGULATION A OFFERING STATEMENT
### UNDER THE SECURITIES ACT OF 1933

### Item 1. Issuer Information

**Exact name of issuer:** Dare Bioscience, Inc.

**Jurisdiction of Incorporation/Organization:** DE

**Year of Incorporation:** 2005

**CIK:** 0001401914

**I.R.S. Employer Identification Number:** 99-2600308

**Primary Standard Industrial Classification Code:** 2834

**Total number of full-time employees:** 21

**Total number of part-time employees:** 3

**Address of Principal Executive Offices:** 3655 NOBEL DRIVE, SUITE 260, SAN DIEGO, CA 92122

**Company Phone:** 858-926-7655

**Person to contact:** Edwin Astudillo

### Financial Statements

**Balance Sheet Information**

| Metric                                   | Amount       |
|:---|:---|
| Cash and Cash Equivalents                | $24711356.00 |
| Investment Securities                    | $0.00        |
| Accounts and Notes Receivable            | $0.00        |
| Property, Plant and Equipment (PP&E)     | $1558890.00  |
| Total Assets                             | $32474563.00 |
| Accounts Payable and Accrued Liabilities | $1925870.00  |
| Long-Term Debt                           | $5946242.00  |
| Total Liabilities                        | $29631929.00 |
| Total Stockholders' Equity               | $2842634.00  |
| Total Liabilities and Equity             | $32474563.00 |

**Statement of Comprehensive Income Information**

| Metric                                    | Amount        |
|:---|:---|
| Total Revenues                            | $1030193.00   |
| Costs and Expenses Applicable to Revenues | $295799.00    |
| Depreciation and Amortization             | $1634486.00   |
| Net Income                                | $-13399274.00 |
| Earnings Per Share - Basic                | -1.20         |
| Earnings Per Share - Diluted              | -1.20         |

**Auditor Information**

| Metric          | Amount              |
|:---|:---|
| Name of Auditor | Haskell & White LLP |

### Outstanding Securities

| Class                          |   Outstanding | CUSIP     | Publicly Traded       |
|:---|---:|:---|:---|
| Common Stock                   |      14499502 | 23666P200 | Nasdaq Capital Market |
| Series A Convertible Preferred |         65640 | 000000000 | None                  |
| N/A                            |             0 | 000000000 | None                  |

### Item 2. Issuer Eligibility
- [x] The issuer certifies that all of the statements in this part are true.

### Item 3. Application of Rule 262
- [x] The issuer certifies that it is not disqualified and has not been involved in any disqualifying event.

### Item 4. Summary Information Regarding the Offering

**Tier:** Tier2

**Financial Statement Status:** Audited

**Type of Securities Offered:** Equity (common or preferred stock)

**Is this a delayed or continuous offering?** Yes

**Was or is the offering to take place within one year after qualification?** No

**Was or is the offering to commence within two days after qualification?** Yes

**Is this a best efforts offering?** Yes

**Was there any solicitation of interest?** No

**Are there any resale securities by affiliates of the issuer?** No

**Offering Amounts**

| Description                                                     | Amount       |
|:---|:---|
| Number of securities offered                                    | 4854000      |
| Number of securities outstanding                                | 65640        |
| Price per security                                              | $5.00        |
| Issuer's aggregate offering price                               | $24270000.00 |
| Aggregate offering price of securities held by security holders | $0.00        |
| Aggregate price of securities offered concurrently              | $0.00        |
| Total aggregate offering price                                  | $24270000.00 |

**Anticipated Fees**

| Service Provider   | Name                                                   | Fees       |
|:---|:---|:---|
| Auditor            | Haskell & White LLP                                    | $60000.00  |
| Legal              | Sheppard Mullin Richter & Hampton LLP; Bevilacqua PLLC | $236569.00 |
| Promoters          |  |  |

**Estimated Net Proceeds to the Issuer:** $22213856.00

### Item 5. Jurisdictions in Which Securities are to be Offered

AL, AK, AZ, AR, CA, CO, CT, DE, FL, GA, HI, ID, IL, IN, IA, KS, KY, LA, ME, MD, MA, MI, MN, MS, MO, MT, NE, NV, NH, NJ, NM, NY, NC, ND, OH, OK, OR, PA, RI, SC, SD, TN, TX, UT, VT, VA, WA, WV, WI, WY, DC, PR

### Item 6. Unregistered Securities Issued or Sold Within One Year

**Name of Such Issuer:** Dare Bioscience, Inc.

**Title of Securities Issued:** Common Stock

**Total Amount of Securities Issued:** 1260000

**Amount of such securities sold by principal security holders:** 0

**Aggregate consideration:** $2,857,479 in cash proceeds; computed by totaling the cash proceeds received by the issuer in exchange for the shares issued

**Basis for aggregate consideration:** —

**Securities Act Exemption:** 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506(c) of Regulation D promulgated thereunder. Securities sold solely to an accredited investor.